| P50 | author | Roberto Frau | Q43127453 |
| | Marco Bortolato | Q43127494 |
| P2093 | author name string | Gian Luigi Gessa | |
| | Marco Orrù | |
| | Gian Nicola Aru | |
| | Grant Christopher Luckey | |
| | Gianluca Boi | |
| P2860 | cites work | Cannabinoid receptor localization in brain | Q24558751 |
| | The effects of cannabinoids on the brain | Q28137626 |
| | Presidential Address, 1974. The more or less startling effects of weak prestimulation | Q28215247 |
| | Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review | Q28215767 |
| | Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies | Q28215775 |
| | Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study | Q28259349 |
| | Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 |
| | Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 |
| | Determination and characterization of a cannabinoid receptor in rat brain | Q29618888 |
| | Formation and inactivation of endogenous cannabinoid anandamide in central neurons | Q29620558 |
| | Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults | Q33575973 |
| | Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients | Q33586360 |
| | The neurobiology of startle | Q33721045 |
| | Pharmacology of cannabinoid receptor ligands. | Q33724151 |
| | Behavioral effects of cannabinoid agents in animals | Q33914022 |
| | Pharmacology and effects of cannabis: a brief review | Q33931252 |
| | Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids | Q33933089 |
| | Cannabis and cannabinoid receptors. | Q33994007 |
| | Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon | Q34096935 |
| | Cannabinergic ligands | Q34167536 |
| | Pharmacokinetics and pharmacodynamics of cannabinoids | Q34185013 |
| | Cannabinoid receptor localization in brain: relationship to motor and reward systems | Q34251331 |
| | A primary acoustic startle circuit: lesion and stimulation studies. | Q34278397 |
| | Pharmacology of cannabinoid CB1 and CB2 receptors. | Q34442847 |
| | Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs | Q34520933 |
| | Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 |
| | Cannabinoid addiction: behavioral models and neural correlates. | Q34616145 |
| | Cannabis and psychosis | Q34633228 |
| | Cardiovascular effects of cannabinoids | Q34786849 |
| | Marijuana withdrawal syndrome in the animal model | Q34986723 |
| | Cognitive measures in long-term cannabis users | Q34986734 |
| | Cannabis dependence and tolerance production | Q37886955 |
| | Sensorimotor gating and schizophrenia. Human and animal model studies | Q38140814 |
| | Diazepam and flurazepam: Effects on conditioned fear as measured with the potentiated startle paradigm | Q39249975 |
| | Pharmacology of cannabinoid receptors | Q40437020 |
| | Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients | Q40808959 |
| | Strain-specific facilitation of dopamine efflux by Δ9-tetrahydrocannabinol in the nucleus accumbens of rat: An in vivo microdialysis study | Q41130886 |
| | Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 |
| | Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons | Q42450378 |
| | Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation | Q43612886 |
| | Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. | Q43641975 |
| | Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats | Q43838064 |
| | Differing effects of the cannabinoid agonist, CP 55,940, in an alcohol or Tween 80 solvent, on prepulse inhibition of the acoustic startle reflex in the rat. | Q43980100 |
| | Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats | Q44126671 |
| | Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. | Q44196891 |
| | Testing hypotheses about the relationship between cannabis use and psychosis | Q44487800 |
| | Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats | Q44530990 |
| | Baclofen reverses the reduction in prepulse inhibition of the acoustic startle response induced by dizocilpine, but not by apomorphine | Q44588967 |
| | CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. | Q45111821 |
| | Discrepant findings of clozapine effects on prepulse inhibition of startle: is it the route or the rat? | Q46463702 |
| | Specific attentional dysfunction in adults following early start of cannabis use. | Q48234562 |
| | Cannabinoid transmission and reward-related events | Q48285165 |
| | The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats | Q48615708 |
| | Drug abuse in schizophrenic patients: clinical correlates and reasons for use. | Q48876065 |
| | Strain and age differences in acoustic startle responses and effects of nicotine in rats | Q49212607 |
| | Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. | Q51034553 |
| | How do genes influence marijuana use? The role of subjective effects. | Q51104551 |
| | An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. | Q51139556 |
| | Behavioral and biologic aspects of marijuana use | Q51294928 |
| | Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. | Q52202168 |
| | Differences in response to an acoustic startle stimulus among forty-six rat strains. | Q52219568 |
| | Age, sex and strain comparison of habituation of the startle response in the rat. | Q52266331 |
| | An evaluation of the history of a marijuana withdrawal syndrome in a large population. | Q52274587 |
| | Differential effects of apomorphine on prepulse inhibition of acoustic startle reflex in two rat strains. | Q52484204 |
| | Effect of Amphetamine and Catecholamines on Startle Response and General Motor Activity of Albino Rats | Q58998818 |
| | Hallucinogenic Effects of Marijuana as Currently Used | Q70583299 |
| | Substance abuse and onset of psychotic illness | Q70768380 |
| | Clinical relevance of cannabis tolerance and dependence | Q72912415 |
| | Neurobiology of schizophrenia | Q73911147 |
| P433 | issue | 3 | |
| P304 | page(s) | 264-271 | |
| P577 | publication date | 2004-07-28 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. | |
| P478 | volume | 177 | |